Literature DB >> 25889131

Obesity and the metabolic syndrome in pediatric psoriasis.

Iris Gutmark-Little1, Kara N Shah2.   

Abstract

Psoriasis is a common, chronic inflammatory dermatosis that often has its onset during childhood. There is increasing evidence that psoriasis in adults is associated with obesity, the metabolic syndrome, and associated comorbidities, including insulin resistance/type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. This association is postulated to arise, at least in part, as a result of a systemic proinflammatory state that is mediated by adipose tissue. Several recent observational studies suggest that children and adolescents with psoriasis may be at increased risk of being overweight and obese as well as having an increased risk for features of the metabolic syndrome. Such an association raises concern with regards to the long-term health implications for children and adolescents with psoriasis and suggests that better awareness, evaluation, and management of overweight and obese patients and associated metabolic disease are warranted in this population.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25889131     DOI: 10.1016/j.clindermatol.2014.12.006

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  10 in total

1.  Pediatric Psoriasis Comorbidity Screening Guidelines.

Authors:  Emily Osier; Audrey S Wang; Megha M Tollefson; Kelly M Cordoro; Stephen R Daniels; Andrew Eichenfield; Joel M Gelfand; Alice B Gottlieb; Alexa B Kimball; Mark Lebwohl; Nehal N Mehta; Amy S Paller; Jeffrey B Schwimmer; Dennis M Styne; Abby S Van Voorhees; Wynnis L Tom; Lawrence F Eichenfield
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

Review 2.  Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.

Authors:  Giulia Ganzetti; Anna Campanati; Elisa Molinelli; Annamaria Offidani
Journal:  World J Cardiol       Date:  2016-02-26

Review 3.  Psoriasis and comorbid diseases: Epidemiology.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

Review 4.  Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.

Authors:  Stephen Chu-Sung Hu; Cheng-Che E Lan
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

5.  Datura Metel L. Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis and Inhibits Inflammatory Cytokines Production through TLR7/8-MyD88-NF-κB-NLRP3 Inflammasome Pathway.

Authors:  Bing-You Yang; Yan-Gang Cheng; Yan Liu; Yuan Liu; Jin-Yan Tan; Wei Guan; Shuang Guo; Hai-Xue Kuang
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

Review 6.  Skin disease related to metabolic syndrome in women.

Authors:  Angelica Misitzis; Paulo R Cunha; George Kroumpouzos
Journal:  Int J Womens Dermatol       Date:  2019-07-04

7.  Metformin Inhibits HaCaT Cell Proliferation Under Hyperlipidemia Through Reducing Reactive Oxygen Species via FOXO3 Activation.

Authors:  Li Zhang; Xiaoling Liu; Min Huang; Rui Wang; Wenwei Zhu; Yu Li; Lin Shen; Chengxin Li
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-07-22

8.  Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review.

Authors:  Andrea Marani; Giulio Rizzetto; Giulia Radi; Elisa Molinelli; Irene Capodaglio; Annamaria Offidani; Oriana Simonetti
Journal:  Healthcare (Basel)       Date:  2022-06-25

Review 9.  Efficacy and safety of ustekinumab in adolescents.

Authors:  Roselyn Kellen; Nanette B Silverberg; Mark Lebwohl
Journal:  Pediatric Health Med Ther       Date:  2016-09-19

10.  Esculetin Ameliorates Psoriasis-Like Skin Disease in Mice by Inducing CD4+Foxp3+ Regulatory T Cells.

Authors:  Yuchao Chen; Qunfang Zhang; Huazhen Liu; Chuanjian Lu; Chun-Ling Liang; Feifei Qiu; Ling Han; Zhenhua Dai
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.